Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Lifecore Biomedical, Inc. LFCR
$6.54 +0.15% Close, Oct 2, 2026 · NASDAQ · Market cap $245.3M
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The stock is 26% below its highest close of the past year.
- Over the past year the stock returned -8.8%, behind the S&P 500 by 23.9 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth, 3-year CAGRBottom 44%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 34%
How cheap the shares are relative to earnings, cash flow and their own history.
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 14%
- 6-month returnTop 15%
- 1-year return vs S&P 500Bottom 37%
- Distance from 52-week highTop 42%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 21%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 16%
- Upside to consensus price targetBottom 9%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 7%
- Maximum drawdown, 3 yearsTop 33%
- Beta vs S&P 500 (lower is better)Bottom 18%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -1.2% | — | Top 34% | |
| Revenue growth, 3-year CAGR | 7.8% | — | Bottom 44% |
Shareholder returns
- Share count change, 1 year
- +1.5%
- Share count change, 3-year CAGR
- +7.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -20.3%
- Average 2-day reaction, last 8
- -0.6%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $6.39
- Target vs current price
- -2.3%
- Analysts with a rating
- 8
- Share rating Buy or Strong Buy
- 50%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +0.0% | +2.1% | +11.0% | +0.9% | — |
| May 6, 2026 | -79.2% | -3.9% | -11.6% | +9.9% | -14.3% |
| Mar 9, 2026 | -5.6% | +0.3% | -6.0% | -41.5% | -21.7% |
| Nov 6, 2025 | +3.3% | -2.2% | +21.4% | +14.8% | +17.7% |
| Aug 7, 2025 | -11.1% | +0.4% | +0.1% | +2.7% | -8.2% |
| Apr 3, 2025 | -235.7% | -5.4% | -13.5% | -5.1% | +12.8% |
| Jan 2, 2025 | +7.4% | -10.4% | -21.9% | -20.1% | -5.2% |
| Oct 4, 2024 | -6.5% | +14.2% | -4.7% | +20.6% | +57.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.19 | -$0.19 | +0.0% | $34.2M |
| May 6, 2026 | -$0.43 | -$0.24 | -79.2% | $23.2M |
| Mar 9, 2026 | -$0.19 | -$0.18 | -5.6% | $34.2M |
| Nov 6, 2025 | -$0.29 | -$0.30 | +3.3% | $31.1M |
| Aug 7, 2025 | -$0.10 | -$0.09 | -11.1% | $36.4M |
| Apr 3, 2025 | -$0.47 | -$0.14 | -235.7% | $35.2M |
| Jan 2, 2025 | -$0.25 | -$0.27 | +7.4% | $32.6M |
| Oct 4, 2024 | -$0.49 | -$0.46 | -6.5% | $24.7M |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 5
- Days above the 200-day average
- 5
- 50-day average slope (20 days)
- -0.0%
- 200-day average slope (20 days)
- -4.8%
- Distance from 50-day average
- +40.2%
- Distance from 200-day average
- +15.4%
- RSI (14)
- 78.4
- Relative volume
- 1.13×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 102.7%
- Volatility vs own 5-year history
- 91th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.83
- Correlation with S&P 500
- 0.38
- Current drawdown from 1-year high
- -25.9%
- Maximum drawdown, 3 years
- -58.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jun 7, 2021 | Mar 17, 2023 | -86.9% | 448 days | Not yet recovered |
| Mar 11, 2021 | Apr 9, 2021 | -18.9% | 20 days | 19 days (May 6, 2021) |
| Dec 11, 2020 | Dec 24, 2020 | -13.9% | 9 days | 16 days (Jan 20, 2021) |
| Oct 6, 2020 | Nov 9, 2020 | -11.6% | 24 days | 12 days (Nov 25, 2020) |
| Jan 20, 2021 | Feb 1, 2021 | -10.8% | 8 days | 6 days (Feb 9, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $245.3M
- 52-week range
- $3.63 – $8.98
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Revenue | $111.3M | $103.3M | $128.3M | $128.9M | $129.5M |
| Gross profit | $39.1M | $28.0M | $41.9M | $40.3M | $40.6M |
| Operating income | -$11.8M | -$21.8M | -$8.8M | -$17.2M | -$1.3M |
| Net income | -$116.7M | -$99.6M | $12.0M | -$38.7M | -$30.8M |
| EPS (diluted) | -$3.97 | -$3.32 | $0.33 | -$1.27 | -$0.93 |
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.9M | $24.7M | $32.6M | $35.2M | $36.4M | $31.1M | $23.2M | $34.2M |
| Net income | -$7.1M | -$16.2M | -$6.6M | -$14.8M | -$1.1M | -$10.0M | -$15.0M | -$6.2M |
| EPS (diluted) | -$0.23 | -$0.53 | -$0.25 | -$0.47 | -$0.06 | -$0.29 | -$0.43 | -$0.19 |
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Operating cash flow | -$22.6M | -$17.4M | $257,000 | -$206,000 | $12.6M |
| Capital expenditure | -$29.9M | -$21.5M | -$18.4M | -$13.4M | -$6.3M |
| Free cash flow | -$52.5M | -$38.9M | -$18.1M | -$13.6M | $6.2M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $4.8M | $0 | $23.9M | -$1.9M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $17.2M
- Total assets
- $229.5M
- Total liabilities
- $263.6M
- Total debt
- $155.1M
- Net debt
- $137.8M
- Shareholders’ equity
- -$34.1M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 2,669,844
- Days to cover
- 15.94
- Change vs previous report
- +10.2%
FINRA short interest, settlement date Sep 15, 2026.